Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL919 Phase 1 SAD in Healthy Participants
NCT05450549Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing DNL919 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events up to 45 days. Started Jul 2022; status: completed.
02
Drugs
DNL919
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05450549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450549.